2.10
+2.44%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About IRLAB Therapeutics
Its shares trade on Nasdaq Stockholm under the ticker IRLAB A.ST. It has been listed since 28 February 2017. In the fiscal year to 31 December 2025, it reported revenue of SEK 57.5m and a net loss of SEK 110.0m. At that date it held total assets of SEK 138.2m and shareholders' equity of SEK 30.7m.
IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Feb 2017
- Employees
- 22
- Website
- irlab.se ↗
Leadership
Pay as last reported
- Ms. Carola LemneIndependent Chairman of the BoardSEK 230,000
- Ms. Kristina TorfgardChief Executive Officer
- Mr. Roy JonebrantInterim Chief Financial Officer
- Dr. Nicholas WatersExecutive Vice President, Head - Research and DevelopmentSEK 3.4m
- Dr. Peder SvenssonDirector - Computational Chemistry and Biology, Chief Information Officer
- Dr. Clas SonessonChief Scientific Officer, since 2016
- Dr. Susanna Holm WatersDirector - Biology and Biostatistics
- Ms. Maria JalmelidChief - Clinical Operations
- Dr. Joakim TedroffChief Medical Officer, since 2016SEK 5,000
- Ms. Cecilia Tivert StenbergHead - Finance, Human Resources Manager
- Mr. Gunnar OlssonDirector, since 2017SEK 450,000
- Mr. Lars AdlerssonIndependent DirectorSEK 250,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- IRLAB Therapeutics AB has several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company focuses on developing innovative therapies for neurological disorders, which enables it to tap into a growing market with limited treatment options. Secondly, IRLAB has a strong research and development team with expertise in neuroscience, allowing it to conduct thorough pre-clinical and clinical studies. This expertise grants the company a competitive advantage in the industry. Furthermore, IRLAB owns a robust intellectual property portfolio, which provides protection for its novel drug candidates and reduces the risk of competitors replicating its success.
Weaknesses
- Despite its strengths, IRLAB Therapeutics AB faces several weaknesses that need to be addressed. The company's current drug pipeline is relatively limited, with only a few candidates in various stages of development. This lack of diversity in its portfolio could limit its ability to generate revenue and face challenges if any of the drug candidates fail in clinical trials. Additionally, IRLAB relies heavily on external partnerships and collaborations for research and development, which can lead to potential delays or dependencies on third-party organizations.
Opportunities
- The pharmaceutical industry presents several opportunities for IRLAB Therapeutics AB. Firstly, the market for neurological disorder treatments is expected to grow significantly in the coming years, driven by an aging population and the increasing prevalence of conditions such as Parkinson's disease. This presents an opportunity for IRLAB to expand its product portfolio and capture a larger market share. Moreover, the company can explore strategic collaborations with other pharmaceutical firms or academic institutions to leverage their expertise and accelerate the development of new therapies.
Threats
- IRLAB Therapeutics AB operates in an industry with various threats that need to be carefully managed. One major threat is the stringent regulatory environment governing the approval and commercialization of new drugs. Compliance with regulatory requirements can significantly impact timelines and increase costs for drug development. Additionally, the pharmaceutical sector is highly competitive, with large and established players dominating the market. This intense competition poses a challenge for IRLAB to differentiate itself and gain market acceptance for its therapies. Furthermore, the company is susceptible to potential patent infringements and intellectual property disputes, which could harm its competitive position.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.